MarketInOut Stock Screener Log In | Sign Up
 

Grifols S.A. ADR

NASDAQ • Healthcare • Drug Manufacturers - General • Quote as of 05/22/2026
Grifols S.A. ADR stock price and volume chart

Company Profile

IndustryDrug Manufacturers - General
SectorHealthcare
ExchangeNASDAQ
Market Capitalization5,529.67 mln
Float417 mln
Earnings Date07/23/2026

EPS

0.71
Decent

P / E

11.24
Fair value

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

-3.75
Highly reliable

1-Year Forecast

10.86
Strong upside

Relative Strength

35 / 100
Underperforming

Business Description

Founded in 1909 and based in Barcelona, Spain, Grifols is a global healthcare company best known for turning human plasma into life-saving medicines used to treat conditions ranging from immune disorders and liver disease to neurological and blood-related illnesses. The company also develops diagnostic tools and testing services that help hospitals and laboratories detect infectious diseases and ensure safe blood transfusions. Beyond plasma, Grifols supplies hospitals with intravenous fluids, clinical nutrition products, and automated systems that streamline hospital operations, while also providing biological materials to pharmaceutical and biotech firms for research and manufacturing purposes.

Key Fundamentals

EPS0.71
P/E11.24
ROE6.55
RPS9.80
ROIC4.45
ROA1.74
Interest Cover2.41
EBITDA, mln1,344
EV / EBITDA14.44
EV / EBIT18.37
Revenue, mln6,691
EV / Revenue2.90

Financial Strength

Altman Z-Score1.06
Piotroski F-Score 4 / 9
Beneish M-Score-3.75
Price to Intrinsic Value0.99
1-Year Target Price10.86
Shiller PE Ratio10.42
Short Ratio7.52

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 4.18% 80 / 100   
1 Month -0.13% 43 / 100   
2 Months -14.38% 18 / 100   
6 Months -6.23% 29 / 100   
1 Year -1.24% 31 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us